Justin Budka
Research Subjects
Justin Budka has a total of 132 co-authors. Here are the top co-authors by number of shared publications:
- Rhine R. Shen
Kite, A Gilead Company, Santa Monica, CA 90404, USA
9 shared publications - Adrian Bot
Capstan Therapeutics, San Diego, California
7 shared publications - Carmen M. Warren
Kite, a Gilead Company, Santa Monica, California
7 shared publications - Christina To
Kite, a Gilead Company, Santa Monica, California
7 shared publications - Craig A. Portell
Division of Hematology and Oncology, University of Virginia Comprehensive Cancer Center, Department of Medicine, Charlottesville, USA
7 shared publications - Ethan G. Aguilar
Division of Blood and Marrow Transplantation, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA
7 shared publications
Latest Publications
- Open Access
- 23 October 2026
- Published by Springer Nature in Nature Medicine
- p. 1-14
Determinants of response to CAR T cell therapy in a multicenter, multi-trial cohort analysis of patients with lymphoma
In patients with non-Hodgkin lymphoma (NHL) treated with chimeric antigen receptor (CAR) T cell therapy, factors associated with efficacy overlap with prognostic biomarkers. Currently, there is no consensus on optimal product characteristics. We analyzed the phenotypic attributes of the anti-CD19 CAR T therapy axicabtagene ciloleucel (axi-cel) from 580 patients with NHL across multiple clinical trials with long-term follow-up (median, 41.9 months). A high proportion of naive-like (CCR7 + CD45RA + ) T cells was the most significant feature associated with prolonged progression-free survival (PFS; hazard ratio = 0.46, 95% confidence interval: 0.31−0.68, P = 9.8 × 10 −5 , high versus low naive-like T cell groups) without impacting safety. The relationship between naive-like T cells and efficacy was independent of tumor microenvironment characteristics (assessed in 112 patients). In multivariate models, the naive-like phenotype outperformed clinicopathologic features such as inflammatory markers and tumor burden, remaining significant after adjusting for product expansion. An inverse correlation was observed between prior lines of therapy and the proportion of naive-like T cells in both product and matched apheresis samples, suggesting a benefit of earlier intervention. The key findings were validated in an independent cohort of 203 patients treated with axi-cel-based therapy or brexucabtagene autoleucel. Mass cytometry by time-of-flight analysis of products from a subgroup of 116 patients confirmed an association between a CD8 naive-like T cell phenotype lacking expression of exhaustion markers, such as TIGIT, LAG-3 and PD-1, and PFS. The evidence generated by this study has the potential to advance the development of more effective cellular therapies.
- 23 October 2026
- Published by Springer Nature in Nature Medicine
- p. 1-14
Open AccessDeterminants of response to CAR T cell therapy in a multicenter, multi-trial cohort analysis of patients with lymphoma
In patients with non-Hodgkin lymphoma (NHL) treated with chimeric antigen receptor (CAR) T cell therapy, factors associated with efficacy overlap with prognostic biomarkers. Currently, there is no consensus on optimal product characteristics. We analyzed the phenotypic attributes of the anti-CD19 CAR T therapy axicabtagene ciloleucel (axi-cel) from 580 patients with NHL across multiple clinical trials with long-term follow-up (median, 41.9 months). A high proportion of naive-like (CCR7 + CD45RA + ) T cells was the most significant feature associated with prolonged progression-free survival (PFS; hazard ratio = 0.46, 95% confidence interval: 0.31−0.68, P = 9.8 × 10 −5 , high versus low naive-like T cell groups) without impacting safety. The relationship between naive-like T cells and efficacy was independent of tumor microenvironment characteristics (assessed in 112 patients). In multivariate models, the naive-like phenotype outperformed clinicopathologic features such as inflammatory markers and tumor burden, remaining significant after adjusting for product expansion. An inverse correlation was observed between prior lines of therapy and the proportion of naive-like T cells in both product and matched apheresis samples, suggesting a benefit of earlier intervention. The key findings were validated in an independent cohort of 203 patients treated with axi-cel-based therapy or brexucabtagene autoleucel. Mass cytometry by time-of-flight analysis of products from a subgroup of 116 patients confirmed an association between a CD8 naive-like T cell phenotype lacking expression of exhaustion markers, such as TIGIT, LAG-3 and PD-1, and PFS. The evidence generated by this study has the potential to advance the development of more effective cellular therapies.
- 24 July 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 11 (121)
Genomic correlates of clinical CAR T cell activity
Germline variants influence immune checkpoint inhibitor responses, but their role in engineered immune cell therapies, such as chimeric antigen receptor T cells (CAR T cells), remains unclear. We integrated whole germline sequencing from patients with lymphoma treated with axicabtagene ciloleucel CAR T cell products in the ZUMA-1 and ZUMA-7 clinical trials with detailed biomarker and functional analyses to identify variants influencing clinical toxicity and pharmacokinetics. Putative deleterious variants in STXBP2 ( syntaxin binding protein 2 ) were enriched among patients with toxicity in ZUMA-1, although not confirmed in ZUMA-7. Mechanistically, STXBP2- deficient or variant-expressing T cells triggered increased inflammatory cytokine production and macrophage activation. Conversely, variants in ADAMTSL3 , a TGFβ (transforming growth factor–β) signaling regulator, correlated with protection from toxicity across both trials. Furthermore, variants in PTPN22 , a negative regulator of T cell receptor signaling, strongly associated with enhanced CAR T cell expansion, a key determinant of efficacy. Together, these findings demonstrate that germline genetics shape the safety and activity of engineered immune cell therapies, affecting future design and patient management.
- 24 July 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 11 (121)
Genomic correlates of clinical CAR T cell activity
Germline variants influence immune checkpoint inhibitor responses, but their role in engineered immune cell therapies, such as chimeric antigen receptor T cells (CAR T cells), remains unclear. We integrated whole germline sequencing from patients with lymphoma treated with axicabtagene ciloleucel CAR T cell products in the ZUMA-1 and ZUMA-7 clinical trials with detailed biomarker and functional analyses to identify variants influencing clinical toxicity and pharmacokinetics. Putative deleterious variants in STXBP2 ( syntaxin binding protein 2 ) were enriched among patients with toxicity in ZUMA-1, although not confirmed in ZUMA-7. Mechanistically, STXBP2- deficient or variant-expressing T cells triggered increased inflammatory cytokine production and macrophage activation. Conversely, variants in ADAMTSL3 , a TGFβ (transforming growth factor–β) signaling regulator, correlated with protection from toxicity across both trials. Furthermore, variants in PTPN22 , a negative regulator of T cell receptor signaling, strongly associated with enhanced CAR T cell expansion, a key determinant of efficacy. Together, these findings demonstrate that germline genetics shape the safety and activity of engineered immune cell therapies, affecting future design and patient management.
- Open Access
- 11 February 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (4) , 1023-1034
Ibrutinib exposure correlates with improved efficacy of CAR T cells in patients with mantle cell lymphoma
The pivotal ZUMA-2 trial evaluated the chimeric antigen receptor (CAR) T-cell therapy brexucabtagene autoleucel (brexu-cel) for the treatment of relapsed/refractory (R/R) mantle cell lymphoma (MCL), and ultimately led to the approval of brexu-cel for R/R MCL. Here we report a retrospective analysis of data and samples from ZUMA-2, analyzed by exposure to class of Bruton tyrosine kinase inhibitor (BTKi; first-generation ibrutinib vs second-generation acalabrutinib) in a treatment line before brexu-cel. We found that the ibrutinib-exposed group had significantly greater duration of progression-free survival, greater CAR T-cell expansion, and more CAR T-cell–related toxicity than the acalabrutinib-exposed group. Brexu-cel products from the ibrutinib-treated patients had increased frequencies of T helper 17 cells and transcriptional signatures associated with cytotoxic function. Seven days after infusion, peripheral blood CAR T cells from ibrutinib-exposed patients showed more pronounced effector memory differentiation, which independently correlated to clinical response to brexu-cel. In contrast, brexu-cel products from acalabrutinib-treated patients were enriched for central memory phenotypes and less effector differentiated at day 7 after infusion. Our findings revealed CAR T-cell phenotypic associations with previous BTKi use, and highlight BTKi exposure as a potentially important clinical variable in ZUMA-2 worthy of further study in efforts to improve CAR T-cell therapies. This trial was registered at www.ClinicalTrials.gov as NCT02601313.
- 11 February 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (4) , 1023-1034
Open AccessIbrutinib exposure correlates with improved efficacy of CAR T cells in patients with mantle cell lymphoma
The pivotal ZUMA-2 trial evaluated the chimeric antigen receptor (CAR) T-cell therapy brexucabtagene autoleucel (brexu-cel) for the treatment of relapsed/refractory (R/R) mantle cell lymphoma (MCL), and ultimately led to the approval of brexu-cel for R/R MCL. Here we report a retrospective analysis of data and samples from ZUMA-2, analyzed by exposure to class of Bruton tyrosine kinase inhibitor (BTKi; first-generation ibrutinib vs second-generation acalabrutinib) in a treatment line before brexu-cel. We found that the ibrutinib-exposed group had significantly greater duration of progression-free survival, greater CAR T-cell expansion, and more CAR T-cell–related toxicity than the acalabrutinib-exposed group. Brexu-cel products from the ibrutinib-treated patients had increased frequencies of T helper 17 cells and transcriptional signatures associated with cytotoxic function. Seven days after infusion, peripheral blood CAR T cells from ibrutinib-exposed patients showed more pronounced effector memory differentiation, which independently correlated to clinical response to brexu-cel. In contrast, brexu-cel products from acalabrutinib-treated patients were enriched for central memory phenotypes and less effector differentiated at day 7 after infusion. Our findings revealed CAR T-cell phenotypic associations with previous BTKi use, and highlight BTKi exposure as a potentially important clinical variable in ZUMA-2 worthy of further study in efforts to improve CAR T-cell therapies. This trial was registered at www.ClinicalTrials.gov as NCT02601313.
- Open Access
Genomic correlates of clinical CAR-T cell activity
Chimeric antigen receptor (CAR)-T cell therapies demonstrate potent anti-tumor efficacy in hematologic malignancies, yet clinical outcomes remain unpredictable due to the bespoke nature of the treatment, which is manufactured from each patient’s own T-cells. While germline variants are known to influence response to immune checkpoint inhibitors 1, 2 , their role in CAR-T cell therapy is unknown. Here, we pair whole-genome germline sequencing of lymphoma patients from the ZUMA-1 3 and ZUMA-7 4 clinical trials of axicabtagene ciloleucel, along with correlative biomarkers and functional assays, to ascertain the impact of germline variants on CAR-T cell behavior. Hypothesizing shared mechanisms of the most common toxicities of CAR-T cells, namely cytokine release syndrome (CRS) with hemophagocytic lymphohistiocytosis (HLH)—a hyperinflammatory syndrome driven by T cell overactivation 5 , we first looked within 17 canonical HLH-associated genes 6 , and identified putative deleterious STXBP2 variants in 15% of ZUMA-1 patients with toxicity, which were absent in control subjects who did not experience high grade toxicity. Subjects with these variants had elevated baseline IFN-γ and inflammatory cytokines, findings that were recapitulated in engineered STXBP2 -deficient and STXBP2 -variant-expressing primary CAR-T cells derived from healthy donors. However, STXBP2 variant enrichment was absent in ZUMA-7 for this toxicity phenotype, possibly reflecting differences in underlying disease burden and evolving clinical management between the trials. A more expansive genome-wide analysis revealed ADAMTSL3 (a negative regulator of TGFβ 7 ) as the only gene nominally enriched for putative deleterious variants in both ZUMA-1 and ZUMA-7 among control subjects, suggesting a protective effect. Finally, we focused on associations between germline variants and CAR-T cell expansion after infusion, a more objective and granular continuous variable that is strongly associated with clinical response across most CAR-T products 8 . We found a strong association between PTPN22 , a known negative regulator of T-cell activation 9–12 and an autoimmune risk gene 13, 14 , variant status and CAR-T cell expansion in both ZUMA-1 and ZUMA-7, with the patients having the highest level of CAR-T expansion across clinical trials harboring variants in the gene. Together, these findings demonstrate the first clear association between germline variants and the clinical behavior of engineered immune cell therapies, which has implications for cellular therapy design, monitoring, testing, clinical trial design, and patient care.
Open AccessGenomic correlates of clinical CAR-T cell activity
Chimeric antigen receptor (CAR)-T cell therapies demonstrate potent anti-tumor efficacy in hematologic malignancies, yet clinical outcomes remain unpredictable due to the bespoke nature of the treatment, which is manufactured from each patient’s own T-cells. While germline variants are known to influence response to immune checkpoint inhibitors 1, 2 , their role in CAR-T cell therapy is unknown. Here, we pair whole-genome germline sequencing of lymphoma patients from the ZUMA-1 3 and ZUMA-7 4 clinical trials of axicabtagene ciloleucel, along with correlative biomarkers and functional assays, to ascertain the impact of germline variants on CAR-T cell behavior. Hypothesizing shared mechanisms of the most common toxicities of CAR-T cells, namely cytokine release syndrome (CRS) with hemophagocytic lymphohistiocytosis (HLH)—a hyperinflammatory syndrome driven by T cell overactivation 5 , we first looked within 17 canonical HLH-associated genes 6 , and identified putative deleterious STXBP2 variants in 15% of ZUMA-1 patients with toxicity, which were absent in control subjects who did not experience high grade toxicity. Subjects with these variants had elevated baseline IFN-γ and inflammatory cytokines, findings that were recapitulated in engineered STXBP2 -deficient and STXBP2 -variant-expressing primary CAR-T cells derived from healthy donors. However, STXBP2 variant enrichment was absent in ZUMA-7 for this toxicity phenotype, possibly reflecting differences in underlying disease burden and evolving clinical management between the trials. A more expansive genome-wide analysis revealed ADAMTSL3 (a negative regulator of TGFβ 7 ) as the only gene nominally enriched for putative deleterious variants in both ZUMA-1 and ZUMA-7 among control subjects, suggesting a protective effect. Finally, we focused on associations between germline variants and CAR-T cell expansion after infusion, a more objective and granular continuous variable that is strongly associated with clinical response across most CAR-T products 8 . We found a strong association between PTPN22 , a known negative regulator of T-cell activation 9–12 and an autoimmune risk gene 13, 14 , variant status and CAR-T cell expansion in both ZUMA-1 and ZUMA-7, with the patients having the highest level of CAR-T expansion across clinical trials harboring variants in the gene. Together, these findings demonstrate the first clear association between germline variants and the clinical behavior of engineered immune cell therapies, which has implications for cellular therapy design, monitoring, testing, clinical trial design, and patient care.
- 12 December 2024
- Published by American Society of Hematology in Blood
- Vol. 144 (24) , 2490-2502
Baseline immune state and T-cell clonal kinetics are associated with durable response to CAR-T therapy in large B-cell lymphoma
Engineered cellular therapy with CD19-targeting chimeric antigen receptor T cells (CAR-Ts) has revolutionized outcomes for patients with relapsed/refractory large B-cell lymphoma (LBCL), but the cellular and molecular features associated with response remain largely unresolved. We analyzed serial peripheral blood samples ranging from the day of apheresis (day –28/baseline) to 28 days after CAR-T infusion from 50 patients with LBCL treated with axicabtagene ciloleucel by integrating single-cell RNA and T-cell receptor sequencing, flow cytometry, and mass cytometry to characterize features associated with response to CAR-T. Pretreatment patient characteristics associated with response included the presence of B cells and increased absolute lymphocyte count to absolute monocyte count ratio (ALC/AMC). Infusion products from responders were enriched for clonally expanded, highly activated CD8+ T cells. We expanded these observations to 99 patients from the ZUMA-1 cohort and identified a subset of patients with elevated baseline B cells, 80% of whom were complete responders. We integrated B-cell proportion ≥0.5% and ALC/AMC ≥1.2 into a 2-factor predictive model and applied this model to the ZUMA-1 cohort. Estimated progression-free survival at 1 year in patients meeting 1 or both criteria was 65% vs 31% for patients meeting neither criterion. Our results suggest that patients’ immunologic state at baseline affects the likelihood of response to CAR-T through both modulation of the T-cell apheresis product composition and promoting a more favorable circulating immune compartment before therapy. These baseline immunologic features, measured readily in the clinical setting before CAR-T, can be applied to predict response to therapy.
- 12 December 2024
- Published by American Society of Hematology in Blood
- Vol. 144 (24) , 2490-2502
Baseline immune state and T-cell clonal kinetics are associated with durable response to CAR-T therapy in large B-cell lymphoma
Engineered cellular therapy with CD19-targeting chimeric antigen receptor T cells (CAR-Ts) has revolutionized outcomes for patients with relapsed/refractory large B-cell lymphoma (LBCL), but the cellular and molecular features associated with response remain largely unresolved. We analyzed serial peripheral blood samples ranging from the day of apheresis (day –28/baseline) to 28 days after CAR-T infusion from 50 patients with LBCL treated with axicabtagene ciloleucel by integrating single-cell RNA and T-cell receptor sequencing, flow cytometry, and mass cytometry to characterize features associated with response to CAR-T. Pretreatment patient characteristics associated with response included the presence of B cells and increased absolute lymphocyte count to absolute monocyte count ratio (ALC/AMC). Infusion products from responders were enriched for clonally expanded, highly activated CD8+ T cells. We expanded these observations to 99 patients from the ZUMA-1 cohort and identified a subset of patients with elevated baseline B cells, 80% of whom were complete responders. We integrated B-cell proportion ≥0.5% and ALC/AMC ≥1.2 into a 2-factor predictive model and applied this model to the ZUMA-1 cohort. Estimated progression-free survival at 1 year in patients meeting 1 or both criteria was 65% vs 31% for patients meeting neither criterion. Our results suggest that patients’ immunologic state at baseline affects the likelihood of response to CAR-T through both modulation of the T-cell apheresis product composition and promoting a more favorable circulating immune compartment before therapy. These baseline immunologic features, measured readily in the clinical setting before CAR-T, can be applied to predict response to therapy.
- Open Access
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S16 from Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)
Supplementary Fig. 1. Duration of response did not associate with CAR T-cell peak expansion.Supplementary Fig. 2. CAR T-cell peak did not associate with ongoing response in secondline LBCL.Supplementary Fig. 3. Early CAR T-cell expansion correlated with ongoing response.Supplementary Fig. 4. Naive T cells associated with improved outcome.Supplementary Fig. 5. Association between toxicity and central memory T-cell product phenotype.Supplementary Fig. 6. Association of product T-cell phenotypes/subpopulations with CAR Tcell expansion.Supplementary Fig. 7. Naive enriched CAR T-cell product was more efficacious in vitro against tumor cells.Supplementary Fig. 8. Select serum inflammatory and immune-modulatory analytes correlated with reduced efficacy and elevated toxicity at baseline and on day 0.Supplementary Fig. 9. Association of T-cell subsets with posttreatment inflammatory serum analytes.Supplementary Fig. 10. Elevated inflammatory profile at baseline differentially correlated with product phenotype.Supplementary Fig. 11. Naive T-cell phenotype associated with higher peak level of VEGF.Supplementary Fig. 12. Coculture IFN-γ associated with toxicity and T-cell phenotype.Supplementary Fig. 13. Coculture IFN-γ association with toxicity and overall best response (CR versus others) by patient.Supplementary Fig. 14. Association of apheresis CD27+CD28+CD8+ naive T cells with response.Supplementary Fig. 15. T naive phenotype in second-line versus third-line LBCL.Supplementary Fig. 16. Gating strategy for CD27 and CD28 costimulatory markers.
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S16 from Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)
Supplementary Fig. 1. Duration of response did not associate with CAR T-cell peak expansion.Supplementary Fig. 2. CAR T-cell peak did not associate with ongoing response in secondline LBCL.Supplementary Fig. 3. Early CAR T-cell expansion correlated with ongoing response.Supplementary Fig. 4. Naive T cells associated with improved outcome.Supplementary Fig. 5. Association between toxicity and central memory T-cell product phenotype.Supplementary Fig. 6. Association of product T-cell phenotypes/subpopulations with CAR Tcell expansion.Supplementary Fig. 7. Naive enriched CAR T-cell product was more efficacious in vitro against tumor cells.Supplementary Fig. 8. Select serum inflammatory and immune-modulatory analytes correlated with reduced efficacy and elevated toxicity at baseline and on day 0.Supplementary Fig. 9. Association of T-cell subsets with posttreatment inflammatory serum analytes.Supplementary Fig. 10. Elevated inflammatory profile at baseline differentially correlated with product phenotype.Supplementary Fig. 11. Naive T-cell phenotype associated with higher peak level of VEGF.Supplementary Fig. 12. Coculture IFN-γ associated with toxicity and T-cell phenotype.Supplementary Fig. 13. Coculture IFN-γ association with toxicity and overall best response (CR versus others) by patient.Supplementary Fig. 14. Association of apheresis CD27+CD28+CD8+ naive T cells with response.Supplementary Fig. 15. T naive phenotype in second-line versus third-line LBCL.Supplementary Fig. 16. Gating strategy for CD27 and CD28 costimulatory markers.
- Open Access
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S16 from Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)
Supplementary Fig. 1. Duration of response did not associate with CAR T-cell peak expansion.Supplementary Fig. 2. CAR T-cell peak did not associate with ongoing response in secondline LBCL.Supplementary Fig. 3. Early CAR T-cell expansion correlated with ongoing response.Supplementary Fig. 4. Naive T cells associated with improved outcome.Supplementary Fig. 5. Association between toxicity and central memory T-cell product phenotype.Supplementary Fig. 6. Association of product T-cell phenotypes/subpopulations with CAR Tcell expansion.Supplementary Fig. 7. Naive enriched CAR T-cell product was more efficacious in vitro against tumor cells.Supplementary Fig. 8. Select serum inflammatory and immune-modulatory analytes correlated with reduced efficacy and elevated toxicity at baseline and on day 0.Supplementary Fig. 9. Association of T-cell subsets with posttreatment inflammatory serum analytes.Supplementary Fig. 10. Elevated inflammatory profile at baseline differentially correlated with product phenotype.Supplementary Fig. 11. Naive T-cell phenotype associated with higher peak level of VEGF.Supplementary Fig. 12. Coculture IFN-γ associated with toxicity and T-cell phenotype.Supplementary Fig. 13. Coculture IFN-γ association with toxicity and overall best response (CR versus others) by patient.Supplementary Fig. 14. Association of apheresis CD27+CD28+CD8+ naive T cells with response.Supplementary Fig. 15. T naive phenotype in second-line versus third-line LBCL.Supplementary Fig. 16. Gating strategy for CD27 and CD28 costimulatory markers.
- 25 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S16 from Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)
Supplementary Fig. 1. Duration of response did not associate with CAR T-cell peak expansion.Supplementary Fig. 2. CAR T-cell peak did not associate with ongoing response in secondline LBCL.Supplementary Fig. 3. Early CAR T-cell expansion correlated with ongoing response.Supplementary Fig. 4. Naive T cells associated with improved outcome.Supplementary Fig. 5. Association between toxicity and central memory T-cell product phenotype.Supplementary Fig. 6. Association of product T-cell phenotypes/subpopulations with CAR Tcell expansion.Supplementary Fig. 7. Naive enriched CAR T-cell product was more efficacious in vitro against tumor cells.Supplementary Fig. 8. Select serum inflammatory and immune-modulatory analytes correlated with reduced efficacy and elevated toxicity at baseline and on day 0.Supplementary Fig. 9. Association of T-cell subsets with posttreatment inflammatory serum analytes.Supplementary Fig. 10. Elevated inflammatory profile at baseline differentially correlated with product phenotype.Supplementary Fig. 11. Naive T-cell phenotype associated with higher peak level of VEGF.Supplementary Fig. 12. Coculture IFN-γ associated with toxicity and T-cell phenotype.Supplementary Fig. 13. Coculture IFN-γ association with toxicity and overall best response (CR versus others) by patient.Supplementary Fig. 14. Association of apheresis CD27+CD28+CD8+ naive T cells with response.Supplementary Fig. 15. T naive phenotype in second-line versus third-line LBCL.Supplementary Fig. 16. Gating strategy for CD27 and CD28 costimulatory markers.
- Open Access
- 8 January 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S16 from Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)
Supplementary Fig. 1. Duration of response did not associate with CAR T-cell peak expansion.Supplementary Fig. 2. CAR T-cell peak did not associate with ongoing response in secondline LBCL.Supplementary Fig. 3. Early CAR T-cell expansion correlated with ongoing response.Supplementary Fig. 4. Naive T cells associated with improved outcome.Supplementary Fig. 5. Association between toxicity and central memory T-cell product phenotype.Supplementary Fig. 6. Association of product T-cell phenotypes/subpopulations with CAR Tcell expansion.Supplementary Fig. 7. Naive enriched CAR T-cell product was more efficacious in vitro against tumor cells.Supplementary Fig. 8. Select serum inflammatory and immune-modulatory analytes correlated with reduced efficacy and elevated toxicity at baseline and on day 0.Supplementary Fig. 9. Association of T-cell subsets with posttreatment inflammatory serum analytes.Supplementary Fig. 10. Elevated inflammatory profile at baseline differentially correlated with product phenotype.Supplementary Fig. 11. Naive T-cell phenotype associated with higher peak level of VEGF.Supplementary Fig. 12. Coculture IFN-γ associated with toxicity and T-cell phenotype.Supplementary Fig. 13. Coculture IFN-γ association with toxicity and overall best response (CR versus others) by patient.Supplementary Fig. 14. Association of apheresis CD27+CD28+CD8+ naive T cells with response.Supplementary Fig. 15. T naive phenotype in second-line versus third-line LBCL.Supplementary Fig. 16. Gating strategy for CD27 and CD28 costimulatory markers.
- 8 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S16 from Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)
Supplementary Fig. 1. Duration of response did not associate with CAR T-cell peak expansion.Supplementary Fig. 2. CAR T-cell peak did not associate with ongoing response in secondline LBCL.Supplementary Fig. 3. Early CAR T-cell expansion correlated with ongoing response.Supplementary Fig. 4. Naive T cells associated with improved outcome.Supplementary Fig. 5. Association between toxicity and central memory T-cell product phenotype.Supplementary Fig. 6. Association of product T-cell phenotypes/subpopulations with CAR Tcell expansion.Supplementary Fig. 7. Naive enriched CAR T-cell product was more efficacious in vitro against tumor cells.Supplementary Fig. 8. Select serum inflammatory and immune-modulatory analytes correlated with reduced efficacy and elevated toxicity at baseline and on day 0.Supplementary Fig. 9. Association of T-cell subsets with posttreatment inflammatory serum analytes.Supplementary Fig. 10. Elevated inflammatory profile at baseline differentially correlated with product phenotype.Supplementary Fig. 11. Naive T-cell phenotype associated with higher peak level of VEGF.Supplementary Fig. 12. Coculture IFN-γ associated with toxicity and T-cell phenotype.Supplementary Fig. 13. Coculture IFN-γ association with toxicity and overall best response (CR versus others) by patient.Supplementary Fig. 14. Association of apheresis CD27+CD28+CD8+ naive T cells with response.Supplementary Fig. 15. T naive phenotype in second-line versus third-line LBCL.Supplementary Fig. 16. Gating strategy for CD27 and CD28 costimulatory markers.
- Open Access
- 8 January 2024
- Published by American Association for Cancer Research (AACR)
Data from Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)
Treatment resistance and toxicities remain a risk following chimeric antigen receptor (CAR) T-cell therapy. Herein, we report pharmacokinetics, pharmacodynamics, and product and apheresis attributes associated with outcomes among patients with relapsed/refractory large B-cell lymphoma (LBCL) treated with axicabtagene ciloleucel (axi-cel) in ZUMA-7. Axi-cel peak expansion associated with clinical response and toxicity, but not response durability. In apheresis material and final product, a naive T-cell phenotype (CCR7+CD45RA+) expressing CD27 and CD28 associated with improved response durability, event-free survival, progression-free survival, and a lower number of prior therapies. This phenotype was not associated with high-grade cytokine release syndrome (CRS) or neurologic events. Higher baseline and postinfusion levels of serum inflammatory markers associated with differentiated/effector products, reduced efficacy, and increased CRS and neurologic events, thus suggesting targets for intervention. These data support better outcomes with earlier CAR T-cell intervention and may improve patient care by informing on predictive biomarkers and development of next-generation products.Significance:In ZUMA-7, the largest randomized CAR T-cell trial in LBCL, a naive T-cell product phenotype (CCR7+CD45RA+) expressing CD27 and CD28 associated with improved efficacy, decreased toxicity, and a lower number of prior therapies, supporting earlier intervention with CAR T-cell therapy. In addition, targets for improvement of therapeutic index are proposed.This article is featured in Selected Articles from This Issue, p. 4
- 8 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)
Treatment resistance and toxicities remain a risk following chimeric antigen receptor (CAR) T-cell therapy. Herein, we report pharmacokinetics, pharmacodynamics, and product and apheresis attributes associated with outcomes among patients with relapsed/refractory large B-cell lymphoma (LBCL) treated with axicabtagene ciloleucel (axi-cel) in ZUMA-7. Axi-cel peak expansion associated with clinical response and toxicity, but not response durability. In apheresis material and final product, a naive T-cell phenotype (CCR7+CD45RA+) expressing CD27 and CD28 associated with improved response durability, event-free survival, progression-free survival, and a lower number of prior therapies. This phenotype was not associated with high-grade cytokine release syndrome (CRS) or neurologic events. Higher baseline and postinfusion levels of serum inflammatory markers associated with differentiated/effector products, reduced efficacy, and increased CRS and neurologic events, thus suggesting targets for intervention. These data support better outcomes with earlier CAR T-cell intervention and may improve patient care by informing on predictive biomarkers and development of next-generation products.Significance:In ZUMA-7, the largest randomized CAR T-cell trial in LBCL, a naive T-cell product phenotype (CCR7+CD45RA+) expressing CD27 and CD28 associated with improved efficacy, decreased toxicity, and a lower number of prior therapies, supporting earlier intervention with CAR T-cell therapy. In addition, targets for improvement of therapeutic index are proposed.This article is featured in Selected Articles from This Issue, p. 4
- Open Access
- 8 January 2024
- Published by American Association for Cancer Research (AACR)
Data from Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)
Treatment resistance and toxicities remain a risk following chimeric antigen receptor (CAR) T-cell therapy. Herein, we report pharmacokinetics, pharmacodynamics, and product and apheresis attributes associated with outcomes among patients with relapsed/refractory large B-cell lymphoma (LBCL) treated with axicabtagene ciloleucel (axi-cel) in ZUMA-7. Axi-cel peak expansion associated with clinical response and toxicity, but not response durability. In apheresis material and final product, a naive T-cell phenotype (CCR7+CD45RA+) expressing CD27 and CD28 associated with improved response durability, event-free survival, progression-free survival, and a lower number of prior therapies. This phenotype was not associated with high-grade cytokine release syndrome (CRS) or neurologic events. Higher baseline and postinfusion levels of serum inflammatory markers associated with differentiated/effector products, reduced efficacy, and increased CRS and neurologic events, thus suggesting targets for intervention. These data support better outcomes with earlier CAR T-cell intervention and may improve patient care by informing on predictive biomarkers and development of next-generation products.Significance:In ZUMA-7, the largest randomized CAR T-cell trial in LBCL, a naive T-cell product phenotype (CCR7+CD45RA+) expressing CD27 and CD28 associated with improved efficacy, decreased toxicity, and a lower number of prior therapies, supporting earlier intervention with CAR T-cell therapy. In addition, targets for improvement of therapeutic index are proposed.This article is featured in Selected Articles from This Issue, p. 4
- 8 January 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)
Treatment resistance and toxicities remain a risk following chimeric antigen receptor (CAR) T-cell therapy. Herein, we report pharmacokinetics, pharmacodynamics, and product and apheresis attributes associated with outcomes among patients with relapsed/refractory large B-cell lymphoma (LBCL) treated with axicabtagene ciloleucel (axi-cel) in ZUMA-7. Axi-cel peak expansion associated with clinical response and toxicity, but not response durability. In apheresis material and final product, a naive T-cell phenotype (CCR7+CD45RA+) expressing CD27 and CD28 associated with improved response durability, event-free survival, progression-free survival, and a lower number of prior therapies. This phenotype was not associated with high-grade cytokine release syndrome (CRS) or neurologic events. Higher baseline and postinfusion levels of serum inflammatory markers associated with differentiated/effector products, reduced efficacy, and increased CRS and neurologic events, thus suggesting targets for intervention. These data support better outcomes with earlier CAR T-cell intervention and may improve patient care by informing on predictive biomarkers and development of next-generation products.Significance:In ZUMA-7, the largest randomized CAR T-cell trial in LBCL, a naive T-cell product phenotype (CCR7+CD45RA+) expressing CD27 and CD28 associated with improved efficacy, decreased toxicity, and a lower number of prior therapies, supporting earlier intervention with CAR T-cell therapy. In addition, targets for improvement of therapeutic index are proposed.This article is featured in Selected Articles from This Issue, p. 4